Surgically Targeted Radiation Therapy (STaRT) for patients with operable brain tumors

Placed by a neurosurgeon at the time of resection, GammaTile gives patients a head STaRT in the fight against brain tumors, delaying tumor recurrence and potentially extending survival[1]

Limits radiation exposure to healthy tissue, minimizing side effects, including hair loss[2]

Assures 100% treatment compliance for all patients

Reduces patient and caregiver treatment burden in terms of time and travel

How does GammaTile Therapy work?

View our GammaTile Therapy animation.

Are you a clinician interested in GammaTile?

We can answer questions or schedule therapy training.

REFERENCES

1. Nakaji P, Youssef E, Dardis C, et al. Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. Presented at: 2019 AANS Annual Scientific Meeting; April 2019; San Diego, CA.

2. Brachman D, Youssef E, Dardis C, et al. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy. 2019;18(3):S35-S36.

GammaTile Therapy is indicated to deliver radiation therapy for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.
For full safety information, refer to the GammaTile Instructions for Use.